NASDAQ$EWTX
Edgewise Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
Edgewise Therapeutics Inc reported Q2 2024 results with higher R&D spending and a widened net loss.
The company recorded no revenue and a net loss of $31.5 million for the quarter, driven by increased research and development expenses of $30.7 million. Cash and marketable securities totaled $511.8 million, providing runway through at least the next 12 months. The firm continues to advance its clinical programs in muscle diseases while operating at a loss.
- Net loss increased to $31.5 million from $21.5 million in Q2 2023 due to higher R&D costs.
- R&D expenses rose 57% year-over-year to $30.7 million, reflecting expanded clinical trial activity.
- Cash, cash equivalents and marketable securities reached $511.8 million, supporting operations for at least 12 months.
- No revenue was generated as the company remains in clinical development stage.
Headline financials
Revenue & EPS history
Edgewise Therapeutics · Revenue · Quarterly
$0
Forward guidance
The company expects to continue incurring significant losses while advancing its clinical programs but believes existing cash reserves are sufficient to fund operations for at least the next 12 months.
Tailwinds
- Strong liquidity position with $511.8 million in cash and marketable securities
Headwinds
- Continued net losses expected as clinical development progresses
- Increasing R&D expenses anticipated with ongoing trials
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-0.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+16.0%
Q2 2022
Best reaction
-12.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2026 | -1.7% | -4.3% | +2.4% | |
| Q3 2025 | -1.7% | +23.7% | +35.8% | |
| Q2 2025 | -4.1% | -0.9% | +15.2% | |
| Q1 2025 | +2.4% | +1.0% | +5.8% | |
| Q4 2024 | -2.4% | +7.0% | -40.7% | |
| Q3 2024 | -0.7% | -3.9% | -11.0% | |
| Q1 2024 | -12.3% | -16.5% | -15.5% | |
| Q4 2023 | -1.3% | -3.7% | -7.1% | |
| Q3 2023 | -10.7% | +5.5% | +13.0% | |
| Q2 2023 | +3.4% | +12.5% | -3.4% | |
| Q1 2023 | -6.5% | -5.5% | -2.8% | |
| Q4 2022 | -3.0% | -2.8% | -30.3% | |
| Q3 2022 | +1.8% | +2.1% | -5.7% | |
| Q2 2022 | +16.0% | +6.8% | +17.1% | |
| Q1 2022 | +1.6% | -0.8% | -18.9% | |
| Q4 2021 | +13.0% | -2.5% | -19.3% | |
| Q3 2021 | -1.8% | -3.4% | -3.1% | |
| Q2 2021 | -5.6% | -10.6% | -7.9% | |
| Q4 2020 | +5.2% | +4.7% | -1.6% | |
| Q1 2021 | +5.2% | +4.7% | -1.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro